CRISPR Therapeutics to Present at the 2022 BMO Growth & ESG Conference
01 déc. 2022 08h00 HE
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
10 nov. 2022 17h40 HE
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics Announces Poster Presentation on CTX110® at the American Society of Hematology (ASH) 2022 Annual Meeting
03 nov. 2022 09h06 HE
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
01 nov. 2022 16h01 HE
|
CRISPR Therapeutics AG
-Exagamglogene autotemcel (exa-cel), formerly known as CTX001™ submission to the U.S. Food and Drug Administration (FDA) for rolling review expected to begin in November, with completion of the U.S....
CRISPR Therapeutics Announces Planned Transition of Chief Operating Officer
27 oct. 2022 08h30 HE
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Oct. 27, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
05 oct. 2022 08h05 HE
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics to Present at the BMO Biopharma Spotlight Series: Gene Editing and Therapy
29 sept. 2022 08h00 HE
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Sept. 29, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)
28 sept. 2022 08h00 HE
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Sept. 28, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
31 août 2022 08h00 HE
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
08 août 2022 08h00 HE
|
CRISPR Therapeutics AG
-CLIMB-111 and CLIMB-121 fully enrolled; completed regulatory discussions for exagamglogene autotemcel (exa-cel), formerly known as CTX001™, with the European Medicines Agency (EMA) and the Medicines...